Literature DB >> 18399615

Malignant bone tumors.

Kristy Weber1, Timothy A Damron, Frank J Frassica, Franklin H Sim.   

Abstract

Malignant bone tumors represent a small percentage of cancers nationwide and also are much less common than malignant soft-tissue tumors. The rarity of the condition makes it imperative that orthopaedic surgeons in nononcologic practices are able to recognize the symptoms that suggest a possible bony malignancy to avoid inappropriate or delayed treatment. The most common primary malignant bone tumors, osteosarcoma and Ewing's sarcoma, occur in childhood. Chondrosarcoma occurs more frequently in older adults. Rare tumors such as chordoma and adamantinoma have anatomic predilections for the sacrum and tibia, respectively. The primary symptom of a patient with a malignant bone tumor is pain, which often occurs at rest or at night. There are also characteristic findings on physical examination such as swelling or decreased joint range of motion. Patients with a likely malignancy require thorough staging to determine the extent of disease and a well-planned biopsy for accurate diagnosis. The biopsy can be an image-guided needle biopsy or an open incisional biopsy. Knowledge of specific tumor characteristics and treatment options for osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and adamantinoma is important. Patients with osteosarcoma and resectable Ewing's sarcoma are treated with chemotherapy followed by surgical resection. Secondary sarcomas can occur in previously benign bone lesions and require aggressive treatment. Specific techniques are available for the resection of malignant bone tumors from the upper extremities, lower extremities, pelvis, and spine. Reconstruction options include the use of allografts, megaprostheses, and vascularized autografts. There has been a trend toward more prosthetic reconstructions because of early complications with allografts. The care of patients with primary malignant bone tumors requires a multidisciplinary approach to treatment. The orthopaedic oncologist is a vital member of a team composed of musculoskeletal radiologists and pathologists, radiation oncologists, medical and pediatric oncologists, and microvascular surgeons.

Entities:  

Mesh:

Year:  2008        PMID: 18399615

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  13 in total

1.  High long-term local control with sacrectomy for primary high-grade bone sarcoma in children.

Authors:  Alexandre Arkader; Christine H Yang; Vernon T Tolo
Journal:  Clin Orthop Relat Res       Date:  2011-12-03       Impact factor: 4.176

2.  Chondrosarcoma of the para-acetabulum: correlation of imaging features with histopathological grade.

Authors:  Yanqing Kang; Weiwei Yuan; Xiaoyi Ding; Guangbin Wang
Journal:  Radiol Med       Date:  2016-08-23       Impact factor: 3.469

Review 3.  [Diagnostics and treatment of primary bone tumors].

Authors:  T Gösling; C Probst; F Länger; H Rosenthal; U Brunnemer; C Krettek
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

4.  Construction of a Diagnostic Model for Distinguishing Benign or Malignant Bone Cancer by Mining miRNA Expression Data.

Authors:  Yueming Zhang; Jianwei Hu; Tao Li; Shizhu Hao; Xiaotang Wu
Journal:  Biochem Genet       Date:  2022-07-21       Impact factor: 2.220

5.  Comprehensive Analysis of Regulatory Networks of m6A Regulators and Reveals Prognosis Biomarkers in Sarcoma.

Authors:  Boran Pang; Dinghao Luo; Bojun Cao; Wen Wu; Lei Wang; Yongqiang Hao
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

6.  The epidemiology of bone cancer in 0 - 39 year olds in northern England, 1981 - 2002.

Authors:  Rachel Eyre; Richard G Feltbower; Peter W James; Karen Blakey; Emmanuel Mubwandarikwa; David Forman; Patricia A McKinney; Mark S Pearce; Richard J Q McNally
Journal:  BMC Cancer       Date:  2010-07-06       Impact factor: 4.430

7.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells.

Authors:  Yin-He Wang; Zhao-Xia Wang; Yong Qiu; Jin Xiong; Yi-Xin Chen; Deng-Shun Miao; Wei De
Journal:  Mol Cell Biochem       Date:  2009-02-20       Impact factor: 3.396

8.  Small-area analyses of bone cancer diagnosed in Great Britain provide clues to aetiology.

Authors:  Richard J Q McNally; Karen Blakey; Roger C Parslow; Peter W James; Basilio Gómez Pozo; Charles Stiller; Tim J Vincent; Paul Norman; Patricia A McKinney; Michael F Murphy; Alan W Craft; Richard G Feltbower
Journal:  BMC Cancer       Date:  2012-06-27       Impact factor: 4.430

9.  First Confirmed Metastatic Adamantinoma of the Spine: Case Report and Literature Review.

Authors:  Ruben A Morales Ciancio; Alessandro Gasbarrini; Stefano Boriani; Marco Gambarotti
Journal:  Global Spine J       Date:  2014-10-25

10.  TUMOR CONTAMINATION IN THE BIOPSY PATH OF PRIMARY MALIGNANT BONE TUMORS.

Authors:  Marcelo Parente Oliveira; Pablo Moura de Andrade Lima; Roberto José Vieira de Mello
Journal:  Rev Bras Ortop       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.